ACTH Interpretation by Decade of Life

Adrenocorticotropic hormone (ACTH, also called corticotropin) is a pituitary peptide hormone measured in plasma to evaluate the hypothalamic-pituitary-adrenal (HPA) axis. It is a different substance from cosyntropin (synthetic ACTH 1-24, brand name Cortrosyn), which is injected during a stimulation test to provoke an adrenal cortisol response; a basal ACTH blood draw and a cosyntropin stimulation test answer related but distinct questions.

What ACTH tells you, and what it does not

ACTH is released by the anterior pituitary in response to corticotropin-releasing hormone (CRH) from the hypothalamus, and it drives cortisol production in the adrenal cortex. When cortisol is abnormal, ACTH is the test that localizes the problem: a low ACTH alongside low cortisol points toward the pituitary or hypothalamus, while a high ACTH alongside low cortisol points toward the adrenal gland itself. ACTH alone, without a paired cortisol, leaves the most clinically important question unanswered.

Plasma ACTH is measured by immunoassay and is unusually fragile in the tube. It degrades at room temperature, so samples are typically drawn into a chilled EDTA tube and processed quickly. A delayed or unchilled sample is one of the more common reasons a result comes back lower than expected in an otherwise healthy person, and this preanalytical problem should be ruled out before a low ACTH is treated as a diagnosis.

Standard reference range versus "optimal" range

Most clinical laboratories report a broad adult morning reference interval, commonly cited as roughly 7 to 63 pg/mL, though the exact bounds differ by lab and by the specific immunoassay platform used. These intervals are statistical constructs built from mixed-age reference populations; they are not health targets, and different assay platforms have been shown to disagree meaningfully on where the upper limit falls.

Longevity and hormone-optimization practices often describe a narrower "optimal" range, commonly around 10 to 45 pg/mL. This is a functional-medicine convention rather than a value endorsed by a professional endocrine society, and readers should not treat it as a diagnostic threshold. A value between the functional upper bound and the lab's reference ceiling is not, by itself, evidence of disease; it may reflect stress, sleep debt, timing of the draw, or nothing at all. Whether such intermediate values predict future adrenal dysfunction has not been established by controlled evidence and should be treated as plausible but unproven.

This is the core, quotable point of this page: a morning ACTH result must be read against the person's age band, the exact collection time, and a paired cortisol value, because the same number can mean different things at 25 versus 65, and a "normal" range built from a mixed-age population will systematically under-flag abnormal values in older adults, whose average and variance both tend to run higher.

ACTH across the decades: what is established and what is not

The pattern described in older endocrinology literature is that ACTH pulsatility and diurnal amplitude are strongest in young adults and progressively blunt with age, and that mean ACTH values trend modestly upward in later decades even as adrenal responsiveness to stimulation can decline. This general direction is physiologically plausible and consistent with broader aging-and-HPA-axis literature, but precise decade-by-decade mean values, standard deviations, and per-decade rate-of-change figures require verification against the primary studies before they are presented to a reader as fixed numbers. This page intentionally avoids stating exact means and sample sizes that cannot currently be traced to a specific, checked source.

What can be said with more confidence:

• Young adults (roughly 20s to 30s). The HPA axis is typically at its most robust diurnal amplitude in this range. The most common reasons to check ACTH here are suspected Addison disease, unexplained fatigue, or evaluation after an abnormal cortisol result. A very low ACTH in a young adult who is not on exogenous steroids is a reason to consider pituitary imaging, not a reason for reassurance.
• Mid-life (roughly 40s to 50s). Perimenopausal hot flashes are driven partly by noradrenergic activation of CRH neurons and can produce transient ACTH elevation around a hot flash episode, which can confound a single morning draw taken near that event. Declining sex steroids in both women and men may also increase HPA reactivity, though the size of this effect in an individual patient is not predictable from population data.
• Older adults (60s and beyond). Diurnal amplitude tends to flatten, average ACTH and its variability both tend to increase, and adrenal histology changes with age can reduce the gland's responsiveness to a given ACTH signal even as basal ACTH is not markedly elevated. This combination, rising signal with falling response, is the physiologic reason a basal ACTH alone can miss early adrenal insufficiency in an older adult, and why a cosyntropin stimulation test carries more diagnostic weight than a single basal value in this age group. Polypharmacy is a major confounder: inhaled corticosteroids, megestrol acetate, and medroxyprogesterone can all suppress ACTH and mimic or produce secondary adrenal insufficiency, and this should be checked before ordering further workup.
• Pediatric and very elderly extremes. Reference data are sparser at both ends of the age spectrum, and structural lesions, while uncommon, are part of the differential for unexplained central ACTH deficiency at any age. A case report describes a pediatric suprasellar granular cell tumor of the neurohypophysis presenting with pituitary-region dysfunction, illustrating that rare structural lesions belong in the differential for unexplained central hormone deficiency in children, even though such tumors are rare (case report). This is case-level evidence, not population data, and should not be used to estimate risk in an individual patient.

Populations with chronic transfusion-dependent disease are a separate exception worth flagging. Endocrine literature on major beta-thalassemia describes pituitary and adrenal endocrine involvement, plausibly related to iron deposition, as part of the disease's multi-organ endocrine burden (endocrine review). A clinician evaluating an unexpected ACTH pattern in a patient with known transfusion-dependent thalassemia should consider this history rather than defaulting to an age-based explanation.

Paired interpretation: ACTH plus cortisol

A single ACTH value without a same-morning cortisol is usually not enough to answer a clinical question. The four-quadrant logic below is the standard framework used in HPA-axis diagnosis, though exact numeric cutoffs vary by lab and clinical context and should be confirmed with the ordering clinician:

A normal basal ACTH and normal basal cortisol in a symptomatic patient does not rule out partial adrenal insufficiency; this is a recognized limitation of basal testing, which is why a cosyntropin stimulation test exists as the more sensitive follow-up when suspicion remains despite normal basal labs.

What else shifts ACTH, beyond age

• Exogenous glucocorticoids are the most common cause of a suppressed ACTH at any age, including inhaled steroids at higher doses, and this should be the first thing checked before treating a low ACTH as pituitary disease.
• Opioids are understood to suppress CRH and reduce ACTH output in chronic users, though the exact magnitude reported in any single study should be checked against the primary paper before being quoted as a fixed percentage.
• Untreated depression has been associated with HPA axis hyperactivation and higher morning ACTH in some study populations; this is an association, not proof that treating the depression will normalize ACTH in a given patient, though clinical experience suggests it often does.
• Chronic inflammation (rheumatoid arthritis, inflammatory bowel disease, chronic infection) can raise ACTH modestly through cytokine-driven CRH stimulation without primary adrenal disease.
• Higher body mass is associated with an altered cortisol feedback loop in some studies, though the ACTH-specific effect size is not well established.
• High-dose biotin (commonly found in hair, skin, and nail supplements) can interfere with biotin-streptavidin based immunoassays and cause a falsely high or falsely low ACTH depending on the assay design. Regulatory guidance has warned that biotin interference with laboratory immunoassays can occur, and it remains good practice to stop high-dose biotin at least 48 hours before this and related hormone tests.

When basal ACTH is not enough: stimulation testing

When adrenal insufficiency is suspected and basal values are borderline, a cosyntropin (synthetic ACTH 1-24) stimulation test is the standard next step. The 250-mcg dose is the more widely used first-line test; a low-dose 1-mcg protocol has been described in some studies as more sensitive for early or mild secondary adrenal insufficiency, though the exact sensitivity figures reported for either protocol vary by study population and should be verified against the specific paper before being cited as a fixed number. This is guideline-informed testing, not something to interpret from a single home lab result; a clinician should order and interpret it in context.

Collection and handling, because this changes the number

1. Collect in the morning, generally 6 to 8 a.m., fasting.
2. Use a pre-chilled EDTA (lavender-top) tube.
3. Invert gently; do not shake.
4. Keep on ice and get the sample to the lab quickly; ACTH degrades at room temperature.
5. The lab centrifuges cold and freezes plasma if it is not assayed the same day.

An unchilled or delayed sample is a common, fixable reason for an unexpectedly low ACTH in someone who otherwise appears well. Before accepting a surprising low result, ask whether collection protocol was followed.

Evidence boundary: what is established, what is plausible, what is not

Established: ACTH has a real diurnal rhythm with morning values generally higher than evening values; ACTH must be interpreted alongside cortisol to localize adrenal versus pituitary/hypothalamic disease; sample handling and exogenous glucocorticoids meaningfully affect measured values; a cosyntropin stimulation test is the standard confirmatory step when adrenal insufficiency is suspected.

Plausible but not firmly established for individual prediction: that a specific intermediate ACTH value (for example, in the mid-40s to 60s pg/mL range) reliably predicts future adrenal decline in an individual; that a fixed decade-by-decade numeric mean and standard deviation can be applied to a given patient; that lifestyle interventions like improved sleep reliably normalize a borderline-high ACTH within a specific timeframe.

Not established: a consensus, guideline-endorsed "optimal" ACTH range distinct from the standard laboratory reference interval. The 10 to 45 pg/mL functional target described in longevity-medicine practice is a site convention, not a professional society recommendation, and should be labeled as such to patients.

Decision framework: what to do with an ACTH result, by situation

This is not a diagnostic tool and does not replace clinical judgment. It is a structured way to think through the next step once a result is in hand.

When to seek prompt evaluation

The following patterns warrant timely clinical evaluation, generally through the ordering clinician or endocrinology, regardless of age:

• A very low ACTH on repeated testing without an identifiable exogenous steroid source
• A markedly elevated ACTH together with features suggestive of adrenal insufficiency, such as unexplained hyperpigmentation, low sodium, or low blood pressure
• A very high ACTH with normal or high cortisol, which raises concern for an ACTH-producing tumor and should not wait for routine follow-up
• Any cosyntropin-stimulated cortisol that fails to reach the expected response threshold set by the testing lab
• A discordant ACTH/cortisol pattern that is not explained by medication, supplement interference, or collection error after a repeat test

If a patient has symptoms of an adrenal crisis, such as severe vomiting, profound weakness, confusion, or very low blood pressure, this is an emergency and should prompt urgent care rather than waiting for outpatient lab follow-up.

Frequently asked questions

References

• Suprasellar granular cell tumor of the neurohypophysis in a child: unusual presentation in pediatric age of a rare tumor. https://pubmed.ncbi.nlm.nih.gov/23463129/
• New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement. https://pubmed.ncbi.nlm.nih.gov/36010271/

This article is drafted for clinical editorial and qualified medical review and reflects a synthesis of general endocrinology teaching and the specific sources cited above. Numeric claims not tied to a specific verified source in this draft have been intentionally left qualitative pending source verification. It does not provide individualized diagnosis or dosing guidance; interpret any ACTH result together with a clinician who has your full history and paired laboratory values.